1. Home
  2. WVE vs MLKN Comparison

WVE vs MLKN Comparison

Compare WVE & MLKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • MLKN
  • Stock Information
  • Founded
  • WVE 2012
  • MLKN 1905
  • Country
  • WVE Singapore
  • MLKN United States
  • Employees
  • WVE N/A
  • MLKN N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • MLKN Office Equipment/Supplies/Services
  • Sector
  • WVE Health Care
  • MLKN Consumer Discretionary
  • Exchange
  • WVE Nasdaq
  • MLKN Nasdaq
  • Market Cap
  • WVE 915.6M
  • MLKN 1.1B
  • IPO Year
  • WVE 2015
  • MLKN N/A
  • Fundamental
  • Price
  • WVE $7.82
  • MLKN $20.82
  • Analyst Decision
  • WVE Strong Buy
  • MLKN
  • Analyst Count
  • WVE 13
  • MLKN 0
  • Target Price
  • WVE $20.15
  • MLKN N/A
  • AVG Volume (30 Days)
  • WVE 1.2M
  • MLKN 634.8K
  • Earning Date
  • WVE 08-07-2025
  • MLKN 06-25-2025
  • Dividend Yield
  • WVE N/A
  • MLKN 3.53%
  • EPS Growth
  • WVE N/A
  • MLKN N/A
  • EPS
  • WVE N/A
  • MLKN N/A
  • Revenue
  • WVE $104,939,000.00
  • MLKN $3,669,900,000.00
  • Revenue This Year
  • WVE N/A
  • MLKN $4.17
  • Revenue Next Year
  • WVE $1.94
  • MLKN $2.69
  • P/E Ratio
  • WVE N/A
  • MLKN N/A
  • Revenue Growth
  • WVE N/A
  • MLKN 1.14
  • 52 Week Low
  • WVE $5.04
  • MLKN $15.25
  • 52 Week High
  • WVE $16.74
  • MLKN $31.73
  • Technical
  • Relative Strength Index (RSI)
  • WVE 67.70
  • MLKN 66.14
  • Support Level
  • WVE $6.25
  • MLKN $20.14
  • Resistance Level
  • WVE $8.13
  • MLKN $21.42
  • Average True Range (ATR)
  • WVE 0.41
  • MLKN 0.81
  • MACD
  • WVE 0.13
  • MLKN 0.16
  • Stochastic Oscillator
  • WVE 92.82
  • MLKN 85.88

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About MLKN MillerKnoll Inc.

MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract , International Contract & Specialty International & Specialty and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.

Share on Social Networks: